Home › Funds › China Universal Asset Management Co., Ltd. › RPRX

China Universal Asset Management Co., Ltd. position in RPRX

ROYALTY PHARMA PLC · Health Care

China Universal Asset Management Co., Ltd. reported holding 120,547 shares of RPRX (ROYALTY PHARMA PLC) in its Q2 2026 13F filing — a position valued at US$6.8M, representing 0.40% of its reported portfolio and ranking #50 among its reported holdings. China Universal Asset Management Co., Ltd. has disclosed RPRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)120.55K sh
Reported value held$6.76M
Portfolio Weight0.40%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How China Universal Asset Management Co., Ltd.'s RPRX position evolved

China Universal Asset Management Co., Ltd. first disclosed a stake in RPRX in Q3 2023 at 11,523 shares (US$313K). The position peaked in Q2 2026 at 120,547 shares, worth US$6.8M. Across 12 filings, China Universal Asset Management Co., Ltd. increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 120,547 shares valued at US$6.8M — a reduction of -9,900 shares quarter over quarter.. Notable position changes include a 348% increase in Q4 2023 (shares rose 8% over the following quarter), a 66% increase in Q1 2024 (shares fell 13% over the following quarter), a 64% increase in Q1 2026 (shares rose 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 11.52K $312.73K New
Q4 2023 51.67K $1.45M Add
Q1 2024 85.88K $2.61M Add
Q2 2024 52.98K $1.40M Reduce
Q3 2024 86.19K $2.44M Add
Q4 2024 94.21K $2.40M Add
Q1 2025 86.92K $2.71M Reduce
Q2 2025 84.63K $3.05M Reduce
Q3 2025 75.78K $2.67M Reduce
Q4 2025 79.62K $3.08M Add
Q1 2026 130.45K $6.26M Add
Q2 2026 120.55K $6.76M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 50 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$601.4M), Baillie Gifford & Co (US$561.6M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has China Universal Asset Management Co., Ltd. held RPRX?

China Universal Asset Management Co., Ltd. has disclosed RPRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is China Universal Asset Management Co., Ltd.'s current position in RPRX?

As of Q2 2026, China Universal Asset Management Co., Ltd. holds 120.55K shares of RPRX (ROYALTY PHARMA PLC), valued at $6.76M, representing 0.40% of its reported portfolio and ranking #50.

Has China Universal Asset Management Co., Ltd. been buying or selling RPRX?

In the latest 13F filing (Q2 2026), China Universal Asset Management Co., Ltd. reduced its position in RPRX. The position peaked in Q2 2026 at 120.55K shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.